GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its antibody ...

Get the latest new motorcycle news from the experts at MCN. Our dedicated news team have their ears to the ground to provide you with the key stories you need to know about in the world of new bikes.